Roberto Polakiewicz

Roberto Polakiewicz

  • Chief Scientific Officer
  • Ph.D., Hebrew University of Jerusalem
Dr. Polakiewicz has been responsible for Product and Technology Development at Cell Signaling Technology (CST) for the past 7 years. His leadership and direction have created the company’s most valuable intellectual property assets. Dr. Polakiewicz has driven the successful implementation of four generations of novel antibody platform technologies that have been critical to the success of CST. His most recent development, NG-XMT™, an immensely promising technology, holds the potential to launch CST into the field of therapeutic antibodies. Dr. Polakiewicz's research interests span different fields including molecular and cell biology, signal transduction, and cancer. During his 25 years of experience in Research and Technology development, Dr. Polakiewicz has published around 60 peer-reviewed publications, and is an inventor on numerous patents and patent applications. Dr. Polakiewicz received his B.S. in Chemistry and Ph.D. in Molecular Biology from the Hebrew University of Jerusalem, and completed postdoctoral studies at the Whitehead Institute for Biomedical Research at M.I.T.

Selected Publications